Mirum Pharmaceuticals (NasdaqGM:MIRM) reported positive primary endpoint results from its Phase 2b AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV). The trial showed robust antiviral ...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an ...
- AZURE-1 and AZURE-4 to form the basis of Mirum’s U.S. BLA Submission Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase ...
Hepatitis delta virus (HDV), a bloodborne infection that is transmitted through infected blood or other bodily fluids, was recently designated as a Group 1 carcinogen by the International Agency for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results